文献速递血栓与止血

促凝血血小板测定为肝素诱导的血小板减少症提供机制见解和诊断潜力

Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2022-02-07

本研究改良流式细胞术促凝血血小板测定法,使用FcγRIIa反应性供者血小板和血浆样本,检测肝素诱导的血小板减少症(HIT)血浆对血小板激动剂反应的影响。结果显示,仅HIT阳性血浆在GPCR刺激下产生肝素依赖性敏化,且需活性FcγRIIa;该测定在验证队列中盲法识别临床确诊HIT的准确率达98%。

要点

  • HIT阳性血浆在GPCR刺激下产生肝素依赖性促凝血血小板敏化,需活性FcγRIIa。
  • 促凝血血小板测定盲法识别临床确诊HIT的准确率达98%。
  • 促凝血血小板反应较高的样本更可能来自有血栓并发症的患者。

核心结论

  • HIT血浆与血小板激动剂共同增加促凝血血小板比例,可能促进HIT血栓风险。
  • 靶向促凝血血小板活化可能代表一种新的治疗策略。
  • 该测定可能成为快速、临床相关功能测定,用于准确检测病理性HIT抗体。

研究设计与样本

  • 改良先前建立的流式细胞术促凝血血小板测定,纳入血浆样本,使用FcγRIIa反应性供者血小板。
  • 血浆样本为血清素释放试验确诊的HIT(HIT+)或HIT筛查阴性。
  • 在验证队列中盲法评估测定识别临床确诊HIT的准确率。

主要发现

  • 对GPCR刺激,仅HIT+血浆产生肝素依赖性敏化,且需要活性FcγRIIa。
  • 促凝血血小板测定盲法识别临床确诊HIT的准确率达98%。
  • 诱导更高促凝血血小板反应的样本更可能来自有血栓并发症的患者。
  • 凝血酶刺激显著增加HIT+血浆的促凝血血小板反应,该反应不依赖肝素,仅部分被FcγRIIa阻断逆转。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is a prothrombotic, immune-mediated adverse drug reaction associated with high rates of thrombosis-related morbidity and mortality caused by FcγRIIa-activating pathogenic antibodies to PF4-heparin. Procoagulant platelets are a platelet subset that promote thrombin generation, are clinically relevant in prothrombotic diseases, and are formed when platelet G-protein-coupled receptor (GPCR) and ITAM-linked receptors are co-stimulated. OBJECTIVES: We examined the procoagulant platelet response of healthy donors to platelet agonists in the presence of HIT plasma and determined the contribution of FcγRIIa. PATIENTS/METHODS: Our previously established flow cytometry-based procoagulant platelet assay was modified to incorporate plasma samples, performed using FcγRIIa-responsive donor platelets. Plasma samples were serotonin-release assay-confirmed HIT (HIT+), or negative on HIT screening. RESULTS: In response to GPCR stimulation, only HIT+ plasma produced a heparin-dependent sensitization that required active FcγRIIa. As a potential diagnostic tool, the procoagulant platelet assay achieved 98% accuracy in identifying clinically verified HIT when performed blinded to the diagnoses of a validation cohort. Samples inducing a higher procoagulant platelet response were more likely from patients with thrombotic complications. Thrombin stimulation markedly increased the procoagulant platelet response with HIT+ plasma that was heparin independent and only partially reversed by FcγRIIa blockade, possibly reflecting ongoing thrombotic risk after heparin cessation. CONCLUSIONS: We demonstrate that HIT plasma together with platelet agonists increased the procoagulant platelet proportions, which may contribute to thrombotic risk in HIT. Targeting procoagulant platelet activation may represent a novel treatment strategy. This assay may be a rapid, clinically relevant functional assay for accurately detecting pathological HIT antibodies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lee CSM, Selvadurai MV, Pasalic L, et al. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia. J Thromb Haemost. 2022. PMID: 35038779. doi:10.1111/jth.15650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。